Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WCK 5222 (Zidebactam/Cefepime) MAD study in healthy volunteers
NCT02707107Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Mar 2016
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zidebactam in Gram-negative bacterial infection (2 arms), sponsored by Wockhardt. Primary endpoint: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment at 14 days. Started Mar 2016; status: completed.
02
Drugs
zidebactam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT02707107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707107.